Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCM235
- Development stage
- Phase 1
- Lead developer
- Shanghai Bocimed Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
BCM235 is an injectable small molecule prodrug of paracetamol (acetaminophen) being developed by Shanghai Yunsheng Yanxin Biotechnology for the management of acute pain and fever. Designed to overcome the solubility and stability challenges associated with intravenous paracetamol formulations, BCM235 is rapidly converted into its active metabolite, paracetamol, following administration. The drug exerts its analgesic and antipyretic effects primarily by inhibiting prostaglandin synthesis in the central nervous system through the inhibition of cyclooxygenase (COX) enzymes. BCM235 has been evaluated in Phase I and Phase II clinical trials in China, with a specific focus on postoperative pain management and fever reduction.
- Other names
- BCM235 injectionBCM-235 injectionBCM 235 injectionN,N-diethylglycine paracetamol ester hydrochloride
Beyond the preview
Go deeper on BCM235.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCM235.